Although many events in the apoptotic pathway involve the nucleussuch as nuclear condensation, DNA fragmentation, and a requirement for new RNA synthesis-cells lacking nuclei, such as blood platelets, also undergo programmed cell death. As in nucleated cells, platelets possess Bcl-2 family proteins, which are key regulators of the mitochondrial death pathway. These include both pro-survival (Bcl-2, Bcl-x L ) and proapoptotic (Bax, Bak) family members (Bertino et al., 2003) . In addition, platelets possess other key components of the pathway including Apaf-1, caspase-9, and caspase-3. However, it has been difficult to determine whether these factors have detrimental or beneficial effects on platelet survival or biogenesis. That is, do pro-death factors enhance platelet biogenesis by promoting the fragmentation of the platelet progenitor cell, the megakaryocyte, or do they promote platelet death, which typically occurs after a week in the blood stream? Some evidence suggests that proapoptotic Bax promotes production of platelets (Dale and Friese, 2006) , and that overexpression of antiapoptotic Bcl-x L impairs the fragmentation of megakayocytes (Kaluzhny et al., 2002 ; Figure 1 ). These findings contrast with the observation that levels of Bcl-x L protein rapidly decline when platelets are stored, which suggests that Bcl-x L might play an important role in platelet survival (Bertino et al., 2003) . Furthermore, in some circumstances Bax can be antiapoptotic and Bcl-x L can be proapoptotic (Clem et al., 1998; Lewis et al., 1999) . Therefore, it has been challenging to show whether endogenous Bcl-x L plays a critical role in platelet survival in vivo.
Huang, Kile, and colleagues now report that Bcl-x L and Bak regulate the life span of platelets in mice (Mason et al., 2007) . These findings stem from a stunning effort in which mice were treated with the mutagen N-ethyl-N-nitrosourea (ENU) and their first generation offspring were screened for dominant platelet deficiency (thrombocytopenia). Even in simpler organisms this strategy often entails heroic effort and has only rarely been accomplished in mice. Nevertheless, these investigators succeeded in identifying five heritable dominant mutations causing thrombocytopenia. Two of the five mutations (Plt20 and Plt16) mapped to the same segment of chromosome 2. Further haplotype mapping of these mutations and subsequent sequence analysis revealed that each mutation causes a single amino acid change in Bcl-x L , from Tyr15 to Cys (Plt20) and Asn182 to Ile (Plt16).
To further explore the role of Bclx L in thrombocytopenia, the authors examined Bcl-x L heterozygous knockout mice. They found that Bcl-x L heterozygous knockout mice, as in mice with either the Plt20 or the Plt16 mutation, have fewer platelets than wildtype mice, strongly indicating that haploinsufficiency for Bcl-x L causes thrombocytopenia. In contrast, platelet cell numbers were not affected in mice heterozygous for Bcl-2, Bcl-w, or Mcl-1, consistent with previous observations that Bcl-w and Mcl-1 are poorly expressed in human platelets and that levels of Bcl-2 expression are significantly lower than Bcl-x L (Zhang et al., 2007) .
To address the role of Bcl-x L in platelets in vivo, Mason et Platelets are cell fragments lacking nuclei that play a key role in blood clotting. Using an impressive genetic screen involving ENU-mutagenesis of whole mice, Mason et al. (2007) report in this issue their identification of mutations in the antiapoptotic protein Bcl-x L that cause accelerated death of platelets leading to platelet deficiency. The fragmentation of the cytoplasm of megakaryocytes gives rise to platelets, which then circulate in the bloodstream, surviving for an average of 10 days. Mason et al. (2007) subjected mice to ENU mutagenesis and screened their first generation offspring for platelet deficiency. They identified two mutations in the gene encoding the antiapoptotic factor Bcl-x L that give rise to a dominantly inherited reduction in platelet count. Further evidence indicates that Bcl-x L promotes platelet survival through inhibition of the proapoptotic activity of Bak. Bcl-2 family members may also regulate platelet production. Bax promotes production of platelets (Dale and Friese, 2006) , and overexpression of antiapoptotic Bcl-x L impairs the fragmentation of megakayocytes (Kaluzhny et al., 2002) .
and spleen, normal numbers of megakaryocyte progenitors, and normal mature megakaryocyte morphology and ploidy profile. Only minor effects on platelet number were observed in spleens from mice homozygous for the Bcl-x L Plt20 mutation. Next, they found that platelets from Plt16, Plt20, or Bcl-x L heterozygous knockout mice had decreased half-lives and were cleared more quickly than wild-type platelets in reciprocal adoptive transfer assays. In addition, the average age of platelets from Bcl-x L Plt20, and Plt16 mice is younger than in wildtype mice, consistent with selective loss of older platelets. Together, the evidence suggests that Bcl-x L deficiency directly reduces platelet life span but does not impair platelet production.
They then sought to understand the molecular mechanisms by which Bcl-x L lengthens the life span of platelets. Both the Plt16 and Plt20 Bcl-x L mutant proteins fully retain their ability to interact with proapoptotic proteins Bak and Bax. However, both mutant proteins are less stable and are degraded more quickly than wild-type Bcl-x L . In mouse embryonic fibroblasts from Plt16 homozygous mice, the basal level of endogenous Bcl-x L was decreased. Consistent with the model that these mutations in Bcl-x L destabilize the protein, mouse embryonic fibroblasts derived from Plt20 or Plt16 homozygous mice were more sensitive than wild-type cells to cell death induced when new protein synthesis was inhibited by cycloheximide but not by other damaging signals such as staurosporine.
An alternative pharmacologic approach was undertaken to demonstrate the importance of Bcl-x L in platelet survival. The small molecule ABT-737, designed to mimic the BH3 domain of proapoptotic Bcl-2 family proteins by inserting into the cleft on Bcl-x L , rapidly induced thrombocytopenia in mice (Mason et al., 2007) and in dogs (Zhang et al., 2007) . This thrombocytopenia was at least partially dependent on caspases (Mason et al., 2007) . Younger platelets were highly resistant to ABT-737 treatment, whereas older platelets were more susceptible, as would be expected given that younger platelets contain more Bcl-x L protein that is gradually lost with platelet aging. Therefore, the amount of Bcl-x L may act as a type of molecular clock (Mason et al., 2007) . Although ABT-737 is proposed to prevent Bcl-x L from binding and inhibiting Bax or Bak, it remains possible that ABT-737 converts Bcl-x L into a pro-death factor that subsequently cooperates with Bax or Bak.
To determine if Bax or Bak is the key mediator of platelet cell death and thrombocytopenia in vivo, Mason et al. examined the effects of Bax and Bak deficiency. Bak knockout, but not Bax knockout, mice exhibited defects in platelet homeostasis and had significantly higher platelet counts and prolonged platelet half-life compared to wild-type mice. More importantly, the absence of Bak reversed the thrombocytopenia of Plt16 or Plt20 mutants, and Bcl-x L heterozygous knockout mice, indicating that Bak is the critical killer of platelets.
Genome-wide, phenotype-driven mutagenesis screens to identify dominant mutations were only recently developed for mice (Hrabe de Angelis et al., 2000) and have been used to identify only a few genes. However, recent advances in technology make it feasible to detect single point mutations in the entire yeast genome or in human chromosomes using a single DNA tiling array (Gresham et al., 2006) . These and other developing technologies, including rapid resequencing of entire genomes, have enormous potential for revealing the functions of mammalian genes and may soon make phenotype-driven mutagenesis screens, exemplified by the heroic efforts of Mason et al., more commonplace.
